Business / Finance

RSS

Florida Institute finalizes funding agreement with TransGenex Nanobiotech

The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with TransGenex Nanobiotech, Inc., a company that is developing nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.

19 Jun 2015

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.

From QIAGEN Manchester Limited 18 Jun 2015

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter Diagnostics supports IFCC-EFLM EuroMedLab 2015 with a showcase of solutions to improve workflow for the diagnostics laboratory. Held from 22-24 June 2015 at the Paris Palais des Congrès France, the company demonstrates its dedication to moving the clinical diagnostic lab forward with its total laboratory solution—from automation, chemistry, immunoassay and haematology to microbiology and its new molecular diagnostics system.

From Beckman Coulter Diagnostics 18 Jun 2015

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.

17 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

AMRI, PerkinElmer form strategic collaboration to accelerate drug discovery

As further evidence of Governor Andrew M. Cuomo's successful establishment of a dynamic and growing bio-pharma sector in Buffalo, New York, Albany Molecular Research Inc. and PerkinElmer, Inc. today announced the formation of a strategic collaboration in connection with the opening of AMRI's drug discovery center as part of the new Buffalo Medical Innovation and Commercialization Hub.

17 Jun 2015

Hill-Rom, Welch Allyn joining forces to advance patient care around the world

Two of the world's leading healthcare technology companies are joining forces to make possible the development of leading-edge solutions that will advance patient care around the world. Hill-Rom Holdings, Inc. and privately-held Welch Allyn, Inc. today announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which Hill-Rom will acquire Welch Allyn for approximately $2.05 billion in cash and stock.

17 Jun 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

CyMedica Orthopedics closes $11.5 million Series A financing

CyMedica Orthopedics, Inc. announced today that it has closed an extension to its Series A financing. The Series A financing was led by investors Research Corporation Technologies, Inc., a Tucson-based venture capital firm, and California Technology Ventures, LLC, a Pasadena-based venture capital fund. The financing also included participation from existing investor Aphelion Capital (Mill Valley, CA) and the founding group of investors.

16 Jun 2015

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.

16 Jun 2015

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority for commercial aseptic filling and testing.

16 Jun 2015

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.

16 Jun 2015

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies.

16 Jun 2015

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services, Inc., a global leader in innovative packaging components and drug delivery systems, hosted a groundbreaking ceremony in Waterford, Ireland today to mark the start of construction for the company's new pharmaceutical component manufacturing facility. Attended by Cllr James Tobin, Mayor of Waterford City and County; Cllr Lola O'Sullivan, Mayor of Waterford Metropolitan District; and other local officials, the event celebrated West's continued investment in Ireland and commitment to the local Waterford community.

16 Jun 2015

Limeade announces acquisition of 9Slides

Limeade, an award-winning employee engagement company, today announced it acquired 9Slides, a leading mobile multimedia learning solution. The 9Slides acquisition demonstrates how Limeade stays ahead in the competitive corporate wellness market.

16 Jun 2015

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Department of Emergency Medicine at Stony Brook University School of Medicine.

16 Jun 2015

SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that, after extensive review of competitive systems, The Anthony Nolan Cell Therapy Centre in Nottingham UK has chosen the SynGenXTM-1000 System and the CryoPRO Workstation to process its umbilical cord blood units. Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen Inc.’s UK distributor, for the supply of SynGen’s products and all post-sales support, starting late summer 2015.

15 Jun 2015

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced that it has expanded its relationship with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, via the signing of a Collaboration Agreement (the "Agreement") pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx multi-parameter diagnostic test for dry eye syndrome ("DES").

15 Jun 2015

Actavis adopts Allergan as its new global name

Actavis plc announced that the company has adopted Allergan plc as its new global name and will begin trading today under a new symbol — AGN — after ringing The Opening Bell at the New York Stock Exchange.

15 Jun 2015

Business / Finance

Florida Institute finalizes funding agreement with TransGenex Nanobiotech

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

AMRI, PerkinElmer form strategic collaboration to accelerate drug discovery

Hill-Rom, Welch Allyn joining forces to advance patient care around the world

Atopix raises additional development capital to investigate OC459 for treatment of asthma

CytomX closes $70 million Series D financing round

CyMedica Orthopedics closes $11.5 million Series A financing

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

Limeade announces acquisition of 9Slides

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

Actavis adopts Allergan as its new global name

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News